CVS plunges 16% after cutting its guidance and citing 'slowing prescription growth'
Sarah Fortune
"Very recent pharmacy network changes in the marketplace are expected to cause some retail prescriptions to begin migrating out of our pharmacies this quarter," said CEO Larry Merlo in the earnings statement.
"In addition, we are currently experiencing slowing prescription growth in the overall market as well as a soft seasonal business. These factors combined are leading us to reduce the mid-point of our guidance for this year by five cents per share."
In a statement, CVS said it expected full-year adjusted earnings per share between $5.77-$5.83, down from a previously announced range of $5.81-$5.89, and below analysts' estimate for $5.85.
For the third quarter, CBS reported net revenue of $44.6 billion, below the forecast for $45.3 billion according to Bloomberg.
The stock lost 15% this year through the market close on Monday.
Markets Insider
- I got a $40K raise using this 30-second strategy. It made me realize loud work, not hard work, always wins.
- Qatar Airways' new CEO explains why it's sticking with the Airbus A380 as other airlines retire the costly superjumbo
- Prince Harry and Meghan found out about Kate Middleton's cancer diagnosis on TV like everyone else, report says
- Sustainable Event Planning
- Ambani, Adani collaborate: RIL picks 26% stake in Adani Power project
- As back-to-office avatars turn casual, comfy sneaker sales pick up pace
- Fresh photographs of Milky Way’s black hole Sgr A* reveal strong, twisted magnetic field similar to M87*
- 8 Lesser-known places to explore in Himachal Pradesh